Month: August 2020

TORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE:SII) (TSX:SII) (“Sprott”) will host a conference call on Friday, August 7, 2020 at 10:00 a.m. ET to discuss its 2020 second quarter results.  Peter Grosskopf, CEO of Sprott will host the call with Whitney George, President of Sprott and Kevin Hibbert, CFO of Sprott. The Company plans to release its financial results at 7:00 a.m. ET the same day.Conference Call DetailsTo participate in the call, please dial (855) 458-4215 ten minutes prior to the scheduled start of the call and provide conference ID 8064077. A taped replay of the conference call will be available until Friday, August 14, 2020 by calling (855) 859-2056, reference number 8064077. The conference call will be webcast live at www.sprott.com and https://edge.media-server.com/mmc/p/wnaue4ybAbout SprottSprott is...

HANGZHOU, China, Aug. 04, 2020 (GLOBE NEWSWIRE) — Canaan Inc. (NASDAQ: CAN) (“Canaan” or the “Company”), a leading high-performance computing solutions provider, today announced that the terms of office of three of its independent directors, namely Mr. Hong Zhang, Mr. Xiaohu Yang, and Ms. Mei Luo, expired on August 1, 2020. All the departing independent directors will not seek appointments nor stand for elections to the board of directors of the Company (the “Board”) following the expiration of their respective terms of office.The nomination committee of the Board has confirmed the addition of Mr. Hongchao Du, Mr. Zhitang Shu, Mr. Wenjun Zhang and Ms. Yaping Zhang as independent directors to the Board, effective August 1, 2020.The nomination committee of the Board has examined the qualifications of the independent...

Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in DecadesVeteran Cardiovascular Commercial Executive Hired to Lead Focused LaunchDUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced the company’s plans to undertake its own focused commercial launch of VASCEPA® (icosapent ethyl) in Europe. Amarin’s plan is subject to review and approval of its Marketing Authorization Application (MAA) by the European Medicines Agency and the European Commission, respectively. The application is in the late stages of review for the reduction of cardiovascular (CV) risk in high-risk patients based on the REDUCE-IT® cardiovascular outcomes study. “With more than 80 million people in Europe with cardiovascular...

LA JOLLA, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference which will be held from September 14 – 18, 2020.  Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Morgan Stanley.About MediciNovaMediciNova, Inc. is a publicly traded biopharmaceutical company focused on developing novel therapeutics for the treatment of diseases with high unmet medical needs...

STAMFORD, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 10:20 a.m. Eastern Standard Time.A video webcast will be available live on the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for approximately 30 days following the conference.About SpringWorks TherapeuticsSpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach...

Phase 1 to focus on Pinion oxide resource conversion and the South Railroad Feasibility StudyVANCOUVER, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) — Gold Standard Ventures Corp. (TSX: GSV; NYSE AMERICAN: GSV) (“Gold Standard” or the “Company”) today announced plans for the 2020 Phase 1 development and exploration program on its 100%-owned/controlled Railroad-Pinion Project in Nevada’s Carlin Trend.  The program includes an estimated 20,410 m of reverse-circulation (RC) and core drilling in 136 holes.  Three drill rigs are currently active on site at Pinion.The Phase 1 2020 program objectives are: (1) convert Pinion Phase 4 to Measured and Indicated confidence level (see attached Pinion Phase 1 drilling illustration); (2) drill test additional near-surface targets at Dark Star with the goal of expanding the oxide resource;...

BANNOCKBURN, Ill., Aug. 04, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2020.Given the merger between HC Group Holdings II, Inc. (“Option Care”) and BioScrip, Inc. (“BioScrip”) to form Option Care Health on August 6, 2019, comparisons to historical periods are relative to legacy Option Care only and incorporate BioScrip results from August 6, 2019 prospectively. Further, as reported on February 3, 2020, the Company completed a reverse 1-for-4 stock split in the first quarter and, as a result, all per share data below is reported incorporating the effect of the reverse stock split as if it was effective for all periods...

CENTOGENE expands ongoing development cooperation with Ministry of Health and Social Protection of the Population of Tajikistan (MoH) to now include COVID-19 testingThe project supports access to testing materials and laboratory devices for SARS-CoV-2 testing – funded by the German Federal Ministry for Economic Cooperation and Development (BMZ) and technical expertise, organizational support, and training provided by CENTOGENECAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 04, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has expanded its ongoing development cooperation with the Ministry of Health and Social...

Board of Directors Declares $0.06 Per Share Cash DividendFinancial Highlights2020 Q2 revenue of $908.2 million, compared to $789.9 million in 2019 Q22020 Q2 net income attributable to Primoris of $33.0 million, or $0.68 per fully diluted share, compared to $17.8 million, or $0.35 per fully diluted share, in 2019 Q22020 Q2 SG&A 5.7% of revenue, compared to 6.2% of revenue in 2019 Q22020 Q2 cash flows from operations of $66.1 million, compared to cash used in operations of $24.4 million in 2019 Q2Total Backlog of $3.5 billion at June 30, 2020° Includes $0.5B related to a major pipeline project in the Mid-AtlanticDALLAS, Aug. 04, 2020 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ GS: PRIM) (“Primoris” or “Company”) today announced financial results for its second quarter ended June 30, 2020.The Company also announced...

Heidelberg, Germany, August 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2020 results on Tuesday, August 11, 2020 and host a conference call at 8:30 a.m. EDT to discuss financial results and corporate developments.The conference call will be available via phone and webcast. To access the first quarter results call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 8855368 approximately 15 minutes prior to the call.To access the live audio webcast of the conference call please visit the “Investors” section of company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived...